| Name | Desvenlafaxine |
| Description | Desvenlafaxine (O-Desmethylvenlafaxine) is a cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a serotonin and noradrenaline reuptake inhibitor (SNRI) and is used as an antidepressive agent. |
| In vitro | In male rats, the oral administration of Desvenlafaxine Succinate penetrates the brain and hypothalamus, significantly increasing extracellular norepinephrine levels. |
| In vivo | Desvenlafaxine Succinate inhibits the neuronal uptake of serotonin (5-HT) and norepinephrine (NE) with IC50 values of 47.3 nM and 531.3 nM, respectively. It exhibits weak binding affinity to human dopamine (DA) transporters at a concentration of 100 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.59 mM), Sonication is recommended.
Ethanol : 3 mg/mL (11.39 mM), Sonication is recommended.
DMSO : 16.67 mg/mL (63.29 mM), Sonication is recommended.
|
| Keywords | WY-45233 Succinate | WY45233 Succinate | SLC6A4 | SERT | SerotoninTransporter | Serotonin Transporter | Norepinephrine (NE) | Inhibitor | inhibit | Desvenlafaxine | 5-HTT | 5HTReceptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
